Strata Critical Medical (BLDE) 2025 Conference September 04, 2025 11:30 AM ET Speaker0My name is Conor Walters, and I'm an associate on the Jefferies Aerospace and Defense and Equity Research Team, and I wanna welcome you all to the twenty twenty five Jefferies Global Industrials Conference. Today, I'm lucky enough to be joined by Will Hayburn, the co CEO and Chief Financial Officer of Strata Critical Medical, formerly Blade Urban Air Mobility. He also served while at Blade Urban Air Mobility as CFO and Hea ...

Company Overview - Blade Air Mobility, Inc. is changing its legal name to Strata Critical Medical, Inc. to focus on mission-critical logistics and medical services for hospitals and healthcare providers [1][2] - The company is one of the largest transporters of human organs for transplant in the United States and provides air transportation and logistics services primarily in the Northeast United States, Southern Europe, and Western Canada [3] Stock Information - The name change will take effect on August 28, 2025, and the company's common stock will begin trading under the symbol "SRTA" on August 29, 2025 [2] - The CUSIP numbers for the company's common stock and warrants will remain unchanged, and no action is required from securityholders [2] Business Model - Blade operates an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies, facilitating a transition to Electric Vertical Aircraft (EVA or eVTOL) for lower-cost, quiet, and emission-free air mobility [3]

Summary of Blade Mobility Conference Call Company Overview - **Company**: Blade Mobility - **Industry**: Organ transportation and logistics Key Points and Arguments 1. **Divestiture Announcement**: Blade Mobility announced the divestiture of its passenger business to Joby Aviation for up to $125 million, which will allow the company to focus solely on its medical and logistics operations [3][4] 2. **Growth in Medical Business**: The medical logistics segment has been the fastest-growing part of the business, with an 18% growth in the most recent quarter, contributing to 85% of the segment's adjusted EBITDA in 2024 [4][34] 3. **Market Opportunity**: The organ transportation market is estimated to be slightly above $1 billion, with potential for an additional $100 million in addressable market growth annually due to increasing organ transplant numbers [14][34] 4. **Regulatory Changes**: Recent regulatory improvements have prioritized the sickest organ recipients, leading to a 50% increase in the distance between donors and recipients over the past five to six years [11][34] 5. **Technological Advancements**: Innovations in perfusion technology have expanded the pool of suitable organ donors and increased the time organs can be transported, enhancing the efficiency of the organ matching process [12][13] 6. **Logistics Model**: Blade operates a flexible logistics model with a mix of owned, dedicated, and flexible aircraft, allowing for rapid response times and cost-effective solutions for transplant centers [17][18][20] 7. **Customer Retention**: The company has achieved a 100% renewal rate on contracts with transplant centers and organ procurement organizations, indicating strong customer satisfaction [30][34] 8. **Ancillary Services Growth**: Ancillary services, such as ground transportation and organ placement services, are growing faster than the overall business and are higher margin, contributing to overall profitability [25][26] 9. **Future Capital Deployment**: Following the divestiture, Blade plans to focus on capital deployment in areas such as internalizing services currently outsourced and potential acquisitions of smaller logistics providers [26][27][28] 10. **Financial Outlook**: The company expects double-digit adjusted EBITDA growth and aims for segment adjusted EBITDA margins to reach the high teens in the midterm [37][38] Additional Important Information - **Customer-Centric Approach**: Blade emphasizes flexibility and customer service, often adjusting logistics to meet specific needs, which has contributed to its high customer retention rate [21][49] - **Impact of Passenger Business Loss**: The divestiture of the passenger business will not affect the utilization of aircraft in the medical segment, as there is no overlap between the two operations [50][51] - **Long-Term Agreements**: Blade has secured long-term agreements with Joby Aviation to continue using rotorcraft for medical purposes, ensuring operational continuity [51] This summary encapsulates the key insights from the Blade Mobility conference call, highlighting the company's strategic focus on its medical logistics business and the growth opportunities within the organ transportation industry.

Core Viewpoint - Joby Aviation's acquisition of Blade Air Mobility's passenger business is seen as a strategic move to enhance its position in the urban air taxi market, despite concerns about the valuation and market reaction [1][9]. Financial Terms of the Deal - Joby will pay Blade up to $125 million in cash or stock, providing immediate market access in New York City and Southern Europe, and ownership of a business that served over 50,000 passengers in 2024 [2][6]. Market Reaction - Following the announcement, Joby’s stock surged 18.8%, adding $2.7 billion to its market cap, but later fell 5% after Blade's second-quarter earnings report, indicating mixed investor sentiment [3][10]. Blade's Business Performance - Blade's second-quarter revenue decreased by 13.2% to $25.7 million, partly due to exiting the Canadian market, while the passenger segment's adjusted EBITDA improved from $0.8 million to $2.4 million [7][8]. Industry Context - The deal highlights the challenges in scaling urban air mobility, where price and access remain significant barriers, as evidenced by Blade's pricing structure [12][13]. Valuation Concerns - Joby, with a market cap exceeding $16 billion, is valued higher than established airlines despite being in a development stage with no material revenue, raising questions about market expectations [10][11]. Strategic Implications - The partnership with Blade, excluding its medical division, positions Joby as a preferred VTOL partner for organ transport, indicating a focus on niche markets within urban air mobility [6].

Company Overview - Blade Air Mobility, Inc. is a technology-powered air mobility platform that provides air transportation and logistics for hospitals across the United States, being one of the largest transporters of human organs for transplant [2] - The company offers helicopter and fixed-wing services primarily in the Northeast United States and Southern Europe, operating an asset-light model with exclusive passenger terminal infrastructure and proprietary technologies [2] Upcoming Events - The Chief Financial Officer, Will Heyburn, will present at the Oppenheimer 28th Annual Technology, Internet & Communications Conference on August 11, 2025, at 2:55 PM ET, with a webcast available for investors [1] Business Model and Technology - Blade's model is designed to facilitate a seamless transition from traditional aircraft to Electric Vertical Aircraft (EVA or eVTOL), aiming for lower-cost air mobility that is both quiet and emission-free [2]

Core Viewpoint - Blade Air Mobility Inc. has announced the sale of its passenger mobility business to Joby Aviation for up to $125 million, transitioning to a pure-play medical logistics company named Strata Critical Medical, which has led to a significant stock price increase followed by a decline due to mixed earnings results [1][2][3] Financial Performance - Blade reported a mixed earnings report, beating revenue expectations but posting a negative earnings per share of five cents, which was worse than the anticipated negative four cents [2] - The medical division contributed nearly 60% of the company's revenue and 84% of its EBITDA, with an 18% year-over-year revenue growth, contrasting with an 8% year-over-year revenue decline in the passenger division [5] Strategic Outlook - The management is optimistic about future growth, expecting continued organic growth and plans to pursue strategic acquisitions with an anticipated $200 million in cash after the sale of the passenger business [6][7] - The company aims to focus on non-emergency medical transport, organ transfer, and time-critical healthcare logistics, which are considered less volatile compared to urban air travel [8] Market Position - Blade estimates the organ logistics market to be worth about $1 billion, with the company currently controlling approximately 30% of this market [11] - The stock forecast indicates a potential upside of 61.29%, with a 12-month price target of $6.25 based on analyst ratings [11] Risks and Considerations - The sale to Joby will be paid entirely in stock, which introduces potential volatility based on Joby's share price, and the deal is expected to close in the first half of 2026, extending the timeline for stock price fluctuations [9][10] - Investors may experience choppy trading conditions until the passenger business is sold, with cautious optimism expected for the stock [12]

Blade Air Mobility (BLDE -6.32%), a provider of air transportation services specializing in both medical organ transport and on-demand passenger flights, released its Q2 2025 results on August 5, 2025. The earnings release highlighted GAAP revenue of $70.8 million, exceeding analyst expectations of $64.1 million (GAAP) by more than $6.7 million, or 10.5%. Earnings per share (GAAP) matched consensus at $(0.04). The most notable development is the planned divestiture of the Passenger division to Joby Aviation ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start August, consider joining Out Fox The Street .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relations ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number 001-39046 BLADE AIR MOBILITY, INC. (Exact name of registrant as specified in its charter) Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 | Delaware | 84-1890381 ...

Financial Data and Key Metrics Changes - The company announced a sale of the Blade passenger business to Joby Aviation for up to $125 million, which is expected to create long-term value for stakeholders [6][9] - Medical revenue grew 17.6% year-over-year to a record $45.1 million in Q2 2025, driven by new transplant center customers and increased demand [18][26] - Adjusted EBITDA margin for the medical segment rose to 13.4% in Q2 2025, compared to 11.4% in Q1 2025, but declined from 14.4% in Q2 2024 [18][20] Business Line Data and Key Metrics Changes - The medical business accounted for approximately 60% of revenue in 2024, up from 12% in 2020, and contributed about 85% of the segment's adjusted EBITDA [6][9] - The passenger business saw a 5.5% decrease in short-distance revenue year-over-year, primarily due to lower revenue in the US segment [20] - The passenger segment adjusted EBITDA tripled year-over-year from $800,000 to $2.4 million, driven by improved flight margins and lower SG&A expenses [22] Market Data and Key Metrics Changes - The company exited the Canadian market in August 2024, impacting short-distance revenue in the US [20] - European operations showed strong revenue growth due to realignment with local partners and operational changes [21] Company Strategy and Development Direction - The company aims to focus on its medical division as a standalone entity, which will be renamed Strata Critical Medical, emphasizing its growth potential in the medical sector [6][9] - A disciplined capital allocation strategy is planned, supported by approximately $200 million in cash from the passenger business sale [12][26] - The company is entering a long-term partnership with Joby Aviation to access eVTOL aircraft for medical use, enhancing its service offerings [15][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects of the medical business, expecting mid-teens revenue growth in the second half of 2025 [26] - The company anticipates improved fleet uptime and adjusted EBITDA margins in the medical segment, projecting margins of approximately 15% [26] - Management noted that the divestiture is expected to be neutral to adjusted EBITDA and free cash flow on a go-forward basis [25][26] Other Important Information - The company ended the quarter with no debt and $113.4 million in cash and short-term investments [25] - The financial impact of the divestiture is expected to be adjusted EBITDA and free cash flow neutral, supported by estimated corporate cost efficiencies of $7 million [10][25] Q&A Session Summary Question: What are the current priorities for capital allocation post-transaction? - Management highlighted opportunities in M&A and organic growth, emphasizing the need for capital to scale the business effectively [29][30] Question: Are there any operational impacts from the divestiture on the medical segment? - Management stated that the company is set up for success as a standalone entity and expects the partnership with Joby to add significant value [32][33] Question: Why was the passenger business sold now? - Management indicated that the market was discounting the value of the passenger business, and the divestiture allows for a clearer focus on the high-growth medical segment [37][38] Question: What is the growth outlook for the medical business? - Management expressed optimism about organic growth driven by new technologies and services, aiming for high teens adjusted EBITDA margins in the long term [41][43] Question: How is the business trending quarter to date? - Management reported strong performance in July, with no signs of seasonal slowdown yet [44] Question: What are the tax implications of the transaction? - Management noted that they have enough NOLs to offset capital gains from the divestiture, expecting minimal cash tax impact [46]